← Browse by Condition
Medical Condition
myelodysplastic syndromes mds
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 3
NCT04064060 Phase 3
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Enrollment
665 pts
Location
United States, Austr...
Sponsor
Celgene
NCT06465953 Phase 3
Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Enrollment
48 pts
Location
United States, Austr...
Sponsor
Institut de Recherches Interna...
NCT06886425
Recruiting
Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
Enrollment
70 pts
Location
France
Sponsor
Assistance Publique Hopitaux D...